Oryzon Genomics (ORY) - ORY-1001 rights back to Oryzon

08:20 EDT 22 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Oryzon Genomics: Roche’s decision to discontinue the development of ORY-1001 and return the rights to Oryzon was major recent news. Roche cited portfolio reprioritisation as the reason and that the decision was not driven by data. While this is a setback in business development for Oryzon, in our view, ORY-1001’s potential has not been compromised and the company indicated that it will continue developing ORY-1001 for both current indications, acute leukaemia and SCLC, before seeking a new partner for late-stage development. On a more positive note, Oryzon reported positive final Phase I data for ORY-2001, which is now ready for further development in several neurological indications. Our valuation is €295m (vs €312m previously) or €8.6/share.
ISIN: ES0167733015

Original Article: Oryzon Genomics (ORY) - ORY-1001 rights back to Oryzon


More From BioPortfolio on "Oryzon Genomics (ORY) - ORY-1001 rights back to Oryzon"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...